-
Why This Pfizer Analyst Is No Longer Bullish On The COVID Stock
Thursday, January 26, 2023 - 5:44pm | 325Read More...Pfizer Inc. (NYSE: PFE) could see headwinds in 2023 due to declining COVID-19 cases, according to a UBS analyst. The Pfizer Analyst: Colin Bristow downgraded Pfizer from Buy to Neutral and lowered the price target from $55 to $47. The primary drivers for this move are the decreasing...
-
Why Eli Lilly Is This Analyst's 'New Top Large Cap Pick'
Thursday, September 22, 2022 - 10:38am | 249Read More...Tirzepatide has been de-risked and Eli Lilly And Co’s (NYSE: LLY) Mounjaro could be the “biggest drug ever,” according to UBS. The Eli Lilly Analyst: Colin Bristow upgraded Eli Lilly from Neutral to Buy while raising the price target from $335 to $363. The Eli Lilly Takeaways...
-
BoA Adds Pfizer To US 1 List; It 'Won't Keep You Up At Night'
Tuesday, February 9, 2016 - 10:52am | 303Read More...Shares of Pfizer Inc. (NYSE: PFE) have been trending south in recent months, and are currently trading around their 52-week low of $28.25. Bank of America Merrill Lynch’s Colin Bristow maintained a Buy rating for the company, with a price objective of $39. Pfizer’s compelling...
-
Bank Of America: New Eli Lilly Data Is 'Game-Changing'
Friday, September 18, 2015 - 1:36pm | 362Read More...Shares of Eli Lilly and Co (NYSE: LLY) surged on Thursday, touching a 52-week high of $89.52. The move higher followed the release of positive data during the EASD conference. Colin Bristow of Bank of America maintained a Buy rating on the stock with a price target boosted to $108 from a previous...
-
Why M&A Doesn't Make Sense For Pfizer Anytime Soon
Thursday, August 13, 2015 - 8:28am | 369Read More...In a report published Wednesday, Bank of America analyst Colin Bristow detailed an investor meeting held with Pfizer Inc. (NYSE: PFE)'s CEO Ian Read and other key senior executives. According to Bristow's meeting, Pfizer noted that one (or several) transformative M&A deal is "...
-
Bank Of America On Merck: 'MAGNIF-TECOS!'
Tuesday, April 28, 2015 - 9:30am | 327Read More...In a report published Tuesday, Bank of America analyst Colin Bristow commented on Merck & Co., Inc. (NYSE: MRK)'s announcement of top-line results for the TECOS trial, noting that the study met its primary endpoint of non-inferiority versus placebo for the composite CV endpoint. The...
-
UPDATE: Bank Of America Reiterates On AbbVie On Move To Standalone Valuation
Friday, October 17, 2014 - 9:44am | 195Read More...In a report published Friday, Bank of America analyst Colin Bristow reiterated a Buy rating on AbbVie Inc (NYSE: ABBV), but lowered the price target from $65.00 to $61.00. In the report, Bank of America noted, “Following ABBV's statement on 10/15/14 communicating its Board's decision to withdraw...
-
Bank Of America: AbbVie's Decision To Reconsider Merger With Shire 'A Surprise To Us'
Wednesday, October 15, 2014 - 10:32am | 290Read More...On Tuesday, AbbVie Inc (NYSE: ABBV) stated that its Board of Directors will meet on October 20 to reconsider its recommendation that shareholders approve the proposed merger agreement with Shire PLC (NASDAQ: SHPG). Shire responded and confirmed that its Board of Directors believe AbbVie should...
-
Bank Of America Believes Anti-Inversion Rules Are Not A Deal-Breaker For AbbVie Inc
Tuesday, September 23, 2014 - 11:16am | 224Read More...In a report published Tuesday, Bank of America analyst Colin Bristow reiterated a Buy rating and $65.00 price target on AbbVie Inc (NYSE: ABBV). In the report, Bank of America noted, “Yesterday, the US Treasury issued a notice outlining changes to various aspects of the tax code with a view to...
-
UPDATE: Bank Of America Reiterates On Merck & Co. On Higher Sales Estimates
Thursday, June 12, 2014 - 7:59am | 212Read More...In a report published Thursday, Bank of America analyst Colin Bristow reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $62.00 to $65.00. In the report, Bank of America noted, “We are increasing our MRK PO to $65 (from $62) based on higher sales estimates for...
-
UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta Case Ruling
Tuesday, April 1, 2014 - 8:04am | 223Read More...In a report published Tuesday, Bank of America analyst Colin Bristow reiterated a Buy rating on Eli Lilly and Co. (NYSE: LLY), and raised the price target from $67.00 to $69.00. In the report, Bank of America noted, “LLY announced that the US District Court has ruled in its favor (vs. TEVA),...
-
UPDATE: Bank of America Initiates Underperform On Lexicon Pharmaceuticals, Says Asset Overvalued
Friday, December 6, 2013 - 8:19am | 194Read More...In a report published Friday, Bank of America Merrill Lynch analyst Colin Bristow initiated an Underperform rating on Lexicon Pharmaceuticals (NASDAQ: LXRX) and initiated a price target of $1.50. In the report, Bank of America Merrill Lynch says "We are initiating coverage of Lexicon...
